A Search for Jet Handedness in Hadronic Z0Z^0 Decays

We have searched for signatures of polarization in hadronic jets from $Z^0 \to q \bar{q}$ decays using the ``jet handedness'' method. The polar angle asymmetry induced by the high SLC electron-beam polarization was used to separate quark jets from antiquark jets, expected to be left- and right-polarized, respectively. We find no evidence for jet handedness in our global sample or in a sample of light quark jets and we set upper limits at the 95% C.L. of 0.063 and 0.099 respectively on the magnitude of the analyzing power of the method proposed by Efremov {\it et al.}Comment: Revtex, 8 pages, 2 figure

Measurement of the Proton and Deuteron Spin Structure Function g_1 in the Resonance Region

We have measured the proton and deuteron spin structure functions g_1^p and g_1^d in the region of the nucleon resonances for W^2 < 5 GeV^2 and $Q^2\simeq 0.5$ and $Q^2\simeq 1.2$ GeV^2 by inelastically scattering 9.7 GeV polarized electrons off polarized $^{15}NH_3$ and $^{15}ND_3$ targets. We observe significant structure in g_1^p in the resonance region. We have used the present results, together with the deep-inelastic data at higher W^2, to extract $\Gamma(Q^2)\equiv\int_0^1 g_1(x,Q^2) dx$. This is the first information on the low-Q^2 evolution of Gamma toward the Gerasimov-Drell-Hearn limit at Q^2 = 0.Comment: 7 pages, 2 figure

Measurement of the Charged Multiplicities in b, c and Light Quark Events from Z0 Decays

Average charged multiplicities have been measured separately in $b$, $c$ and light quark ($u,d,s$) events from $Z^0$ decays measured in the SLD experiment. Impact parameters of charged tracks were used to select enriched samples of $b$ and light quark events, and reconstructed charmed mesons were used to select $c$ quark events. We measured the charged multiplicities: $\bar{n}_{uds} = 20.21 \pm 0.10 (\rm{stat.})\pm 0.22(\rm{syst.})$, $\bar{n}_{c} = 21.28 \pm 0.46(\rm{stat.}) ^{+0.41}_{-0.36}(\rm{syst.})$ $\bar{n}_{b} = 23.14 \pm 0.10(\rm{stat.}) ^{+0.38}_{-0.37}(\rm{syst.})$, from which we derived the differences between the total average charged multiplicities of $c$ or $b$ quark events and light quark events: $\Delta \bar{n}_c = 1.07 \pm 0.47(\rm{stat.})^{+0.36}_{-0.30}(\rm{syst.})$ and $\Delta \bar{n}_b = 2.93 \pm 0.14(\rm{stat.})^{+0.30}_{-0.29}(\rm{syst.})$. We compared these measurements with those at lower center-of-mass energies and with perturbative QCD predictions. These combined results are in agreement with the QCD expectations and disfavor the hypothesis of flavor-independent fragmentation.Comment: 19 pages LaTex, 4 EPS figures, to appear in Physics Letters

Measurements of the Proton and Deuteron Spin Structure Functions g1g_{1} and g2g_{2}

Measurements are reported of the proton and deuteron spin structure functions g1 at beam energies of 29.1, 16.2, and 9.7 GeV and g2 at a beam energy of 29.1 GeV. The integrals of g1 over x have been evaluated at fixed Q**2 = 3 (GeV/c)**2 using the full data set. The Q**2 dependence of the ratio g1/F1 was studied and found to be small for Q**2 > 1 (GeV/c)**2. Within experimental precision the g2 data are well-described by the Wandzura-Wilczek twist-2 contribution. Twist-3 matrix elements were extracted and compared to theoretical predictions. The asymmetry A2 was measured and found to be significantly smaller than the positivity limit for both proton and deuteron targets. A2 for the proton is found to be positive and inconsistent with zero. Measurements of g1 in the resonance region show strong variations with x and Q**2, consistent with resonant amplitudes extracted from unpolarized data. These data allow us to study the Q**2 dependence of the first moments of g1 below the scaling region

Precision measurement of the deuteron spin structure function g1dg^{d}_{1}

We report on a high-statistics measurement of the deuteron spin structure function g[sup d][sub 1] at a beam energy of 29 GeV in the kinematic range 0.029 < x < 0.8 and 1 < Q2 < 10 (GeV/c)2. The integral Gamma [sup d][sub 1] = (integral)[sup 1][sub 0]g[sup d][sub 1]dx evaluated at fixed Q2 = 3 (GeV/c)2 gives 0.042 ± 0.003(stat) ± 0.004(syst). Combining this result with our earlier measurement of g[sup p][sub 1], we find Gamma [sup p][sub 1]- Gamma [sup n][sub 1] = 0.163 ± 0.010(stat) ± 0.016(syst), which agrees with the prediction of the Bjorken sum rule with O( alpha [sup 3][sub s]) corrections, Gamma [sup p][sub 1]- Gamma [sup n][sub 1] = 0.171 ± 0.008. We find the quark contribution to the proton helicity to be Delta q = 0.30 ± 0.06

Measurements of R=sigma_L/sigma_T for 0.03<x<0.1 and Fit to World Data

Measurements were made at SLAC of the cross section for scattering 29 GeV electrons from carbon at a laboratory angle of 4.5 degrees, corresponding to 0.03<x<0.1 and 1.3<Q^2<2.7 GeV^2. Values of R=sigma_L/sigma_T were extracted in this kinematic range by comparing these data to cross sections measured at a higher beam energy by the NMC collaboration. The results are in reasonable agreement with pQCD calculations and with extrapolations of the R1990 parameterization of previous data. A new fit is made including these data and other recent results.Comment: 8 pages, 4 figures, late

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707